PROSTATE cancer patients have been offered hope after North-East scientists identified a new group of molecules that could be targeted to slow tumour growth.

Experts at Newcastle University used an advanced screening technique which found hundreds of genes were affected by the male hormone testosterone. It is believed this could lead to new diagnostic tests and treatments.

Among the 700 genes identified was an important set that add sugar groups – known as glycans - to the surface of prostate cancer cells. This group has never been investigated before.

Results of the research, published in EBioMedicine, suggest that testosterone changes glycans to make cancer cells more likely to survive, grow and spread to other parts of the body.

Scientists say there is the potential to target these glycans which could stop the growth and spread of tumours and save lives.

Dr Jennifer Munkley, Research Associate at the Institute of Genetic Medicine, Newcastle University, co-led the three-year research project with Professor David Elliott.

She said: “Our findings are very significant for future treatments as they identify a new group of molecules in prostate cancer which could be targeted therapeutically.

“Now we have identified these glycans we will be able to develop strategies to inhibit them and help patients with this condition.

Former operating theatre manager David Forrester, 62, of Newcastle, who was diagnosed with prostate cancer four years ago and decided to have surgery to remove his prostate said: “It is absolutely vital that research is done into prostate cancer and experts gain as good an understanding of the condition as possible.

“With two sons and two grandsons, who are at higher risk of developing the disease, I am especially interested in this research.

“It is exciting that Newcastle University is leading the way and it shows what world-class research is going on.”